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We thank Eftychios Siniorakis and colleagues for their thoughtful letter on how repurposing statins and angiotensin receptor blockers (ARBs) for coronavirus disease 2019 (COVID-19) treatment might affect patients with heart failure ([@B1]). Our understanding of the pathophysiology of COVID-19 disease has advanced rapidly in the past few months. The immunological dysregulation associated with the disease and the cardiovascular effects of infection (and especially the role of angiotensin converting enzyme 2 \[ACE2\]) have been comprehensively reviewed ([@B2][@B3][@B7]). Some patients who develop acute respiratory distress syndrome (ARDS) can be severely hypoxic and yet show relatively normal pulmonary compliance ([@B8]). Endothelial dysfunction and intense inflammation seem to be important contributors to their distress ([@B9]). In addition, pulmonary microvascular coagulopathy, sometimes associated with pulmonary or systemic embolization, has added a new dimension to clinical care ([@B10][@B11][@B12]). Many physicians have added anticoagulation to their treatments ([@B13]). Recently, van de Veerdonk and colleagues called attention to the contribution of the kallikrein-kinin system to COVID-19-induced ARDS ([@B14], [@B15]). Although much attention has been focused on the relationship between the renin-angiotensin system (RAS) and COVID-19 ([@B5][@B6][@B7]), there is considerable cross talk between the RAS and kallikrein-kinin systems ([@B14][@B15][@B16]). Experimentally, a reduction in ACE2 activity can impair inactivation of the B1 bradykinin receptor and this can be associated with an increase in inflammation-induced acute lung injury ([@B17]).

This is the backdrop for the concern raised by Siniorakis et al.: some COVID-19 patients might have heart failure and be receiving combination treatment with an angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI). Neprilysin is known to degrade bradykinin, and ARB treatment can increase bradykinin levels ([@B18]). Thus, if bradykinin is involved in the genesis of the intense inflammation and microvascular coagulopathy seen in many COVID-19 patients ([@B11], [@B14], [@B15]), the increase in bradykinin levels that accompanies ARB and neprilyin inhibitor treatment might be harmful. (Angiotensin converting enzyme inhibitors \[ACEIs\] also upregulate bradykinin, and they are more commonly associated with acute episodes of angioedema than are ARBs.) To our knowledge, there have been no reports of COVID-19 patients who were treated with both ARNIs and ARBs or ACEIs.

We believe that physicians should consider combination statin/ARB treatment of severely ill COVID-19 patients ([@B19]). Both drugs have beneficial effects on inflammation, coagulation abnormalities, and endothelial dysfunction. Recently published observational studies suggested that ACEIs, ARBs, and statins are associated with improved outcomes in COVID-19 patients ([@B20], [@B21]), although not all studies have shown this ([@B22]). Whether ARNI treatment of COVID-19 patients would be harmful remains to be determined, although it has been shown to improve endothelial dysfunction in hypertensive rats ([@B23]). The great advantage of ACEIs, ARBs, and statins is that they are widely available as inexpensive generics in resource-poor countries where lockdowns and social distancing would be difficult to implement. The same cannot be said for virtually all of the other COVID-19 treatments now being tested in clinical trials.

This is a response to a letter by Siniorakis et al. (https://doi.org/10.1128/mBio.00946-20).
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